SABCS Meeting 2021 Participation
All times are CST

General Session 1
Tuesday, December 7
8:15 AM
Location: Hall 3
GS1-01 KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer (TNBC)
Presenter: Lajos Pusztai, MD, DPhil

Special Session
Tuesday, December 7
1:00 PM – 4:00 PM
Location: Hall 3
Trust in Science and Healthcare
Panel 2: Diversity in Clinical Trials – From Ideation to Implementation COVID Update
Panelist: Eric P. Winer, MD

Poster Session 1
Wednesday, December 8
7:00 – 8:30 AM
Location: Hall 1
Detection/Diagnosis - Pathology: Diagnostic Pathology
P1-02-02 – Examination of low Her2 expression in breast cancer

Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification
P1-05-02 – Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors
Authors: Foldi J, Reisenbichler E, Pan L, Sorg K, Church SE, Pusztai L.

General Session 2
Wednesday, December 8
10:15 AM

**Location:** Hall 3

**GS2-07.** Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER)

**Presenter:** Lajos Pusztai, MD, DPhil

---

**Poster Session 2**

**Wednesday, December 8**

5:00 – 6:30 PM

**Location:** Hall 1

**Prognostic and Predictive Factors - Predictive Biomarkers for Combined Modality Therapies**

**P2-07-09** – Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer

**Authors:** Kearney MR, Vanguri R, Wang Q, Fenn K, Guo H, Marks D, Hibshoosh H, Kalinsky KM, Connolly E.

**Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive Biomarkers-Other**

**P2-08-03** – PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer

**Authors:** Blenman KRM, Harigopal M, Huang R, Reisenbichler E, Qing T, Ibrahim E, Singh K, Ramkissoon S, Mustimbo R, Ross J, Pusztai L.

**Treatment - Therapeutic Strategies: HER2-Targeted Therapy**


**Authors:** Papautsky EL, Carlson M, Lustberg M

**P2-13-25** – A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer


---

**Spotlight Poster Discussion 5**

**Location:** Stars at Night Ballroom 1&2

**Life After Breast Cancer: Cardiac Health, Fertility Preservation, and Returning to Life**

**Ovarian Reserve and Assisted Reproduction**

**Presenter:** Maryam Lustberg, MD, MPH

**Employment Changes, Sedative Hypnotic Use, and Risk Of Long-Term Chemotherapy Toxicity**

**Presenter:** Tara Sanft, MD

---

**Ongoing Trials Poster Session 1**
Wednesday, December 8
5:00 PM – 6:30 PM
Location: TBA
Endocrine Therapy
OT1-10-01 – The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapy
Authors: O’Shaughnessy JA, Fox JR, Encarnación CA, O’Neal B, Treuner K, Sanft T, Jankowitz RC, Pegram MD, Schnabel CA, Diab SG.

OT1-12-04 – A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

Poster Session 3
Thursday, December 9
7:00 – 8:30 AM
Location: Hall 1
Tumor Cell and Molecular Biology: Genetics - Germline Changes
P3-07-01 – Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes
Authors: Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L.

Spotlight Poster Discussion 9
Location: Hall 4A
Evaluating Emerging and Established Biomarkers
PD9-06 – Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial

Translational Science Forum
Thursday, December 9
2:00 – 3:00 PM
Location: Hall 4A
HER2 Heterogeneity – Basic
Presenter: Kim RM Blenman, PhD, MS

Poster Session 4
Thursday, December 9
5:00 – 6:30 PM
Location: Hall 1
**Tumor Cell and Molecular Biology: Etiology/Carcinogenesis**
P4-03-01 – Budding Tumorigenesis: A novel proposed model for breast cancer tumorigenesis  
**Authors:** Yaghoobi V, Aung TNWE, Moutafi M, Cooke TL, Rimm DL.

**Psychosocial, QOL, and Educational Aspects: QOL - Supportive Care**
P4-10-09 – Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)  
**Authors:** Loeser AL, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Maues J, McGlown S, Lustberg M.

P4-10-11 – Eyebrow/eyelash loss among survivors  
**Authors:** Cathcart-Rake E, Loprinzi CL, Couch F, Olson J, Dulmage B, Lustberg M, Larson N, Ruddy KJ.

P4-10-13 – Area deprivation index and rurality in relation to financial toxicity among breast cancer surgical patients - Investigating geospatial differences in risk profiles  
**Authors:** Corkum JP, Zhu V, Agbafe V, Chu C, Suarez Colen J, Greenup R, Offodile AC.

P4-10-17 – Alopecia among breast cancer survivors  
**Authors:** Cathcart-Rake E, Loprinzi CL, Olson JE, Couch F, Dulmage B, Lustberg M, Larson N, Ruddy KJ.

**Spotlight Poster Discussion 10**
**Location:** Stars at Night Ballroom 1&2

**Novel Immunotherapy Approaches**

PD10-07 – Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies  

**Poster Session 5**
**Friday, December 10**
7:00 – 8:30 AM
**Location:** Hall 1

**Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets**
P5-08-16 – MTAP deletion and synthetic lethality-based drug development for metastatic breast cancer (MBC)  
**Authors:** Pusztai L, Danziger N, Sokol ES, Pavlick DC, Graf R, Ramkissoon S, Huang RSP, Decker BJ, Ross JS.

**Treatment: Therapeutic Strategies - Novel Targets and Targeted Agents**
P5-17-01 – Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models  
**Authors:** Foldi J, Marczyk M, Gunasekharan V, Qing T, Sehgal R, Shan NL, Muthusamy V, Umlau S, Surovtseva YV, Kibbey R, Pusztai L.
Spotlight Poster Discussion 13
Location: Stars at Night Ballroom 1&2
Novel Therapeutics
PD13-03 – Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2– advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1

Spotlight Poster Discussion 15
Location: Hall 4A
Defining Molecular Markers of Endocrine Resistance in Clinic
Chair: Lajos Pusztai, MD, DPhil

Year in Review
Friday, December 10
5:00 – 7:00 PM
Location: Stars at Night Ballroom 1&2
View from the Trenches: What will You do on Monday Morning?
Panelist: Meena Moran, MD